SEARCH

SEARCH BY CITATION

References

  • 1
    Vasquez E, Tanzi  , Benedetti E, Pollak R. Medication noncompliance after kidney transplantation. Am J Health-Syst Pharm 2003; 60: 266269.
  • 2
    Gaston R, Hudson S, Ward M, Jones P, Macon R. Late renal allograft loss: Non-compliance masquerading as chronic rejection. Transplant Proc 1999; 31(Suppl 4A): 21S23S.
  • 3
    Matas A, Humar A, Gillingham K et al. Five preventable causes of kidney graft loss in the 1990s: A single-center analysis. Kidney Int 2002; 62: 704714.
  • 4
    Weng FL, Israni AK, Joffe MM et al. Race and electronically measured adherence to immunosuppressive medications after deceased donor renal transplantation. J Am Soc Nephrol 2005; 16: 18391848.
  • 5
    Ichimaru N, Kakuta Y, Abe T et al. Treatment adherence in renal transplant recipients: A questionnaire survey on immunosuppressants. Transplant Proc 2008; 40: 13621365.
  • 6
    Chisholm M, Mulloy L, DiPiro J. Comparing renal transplant patients’ adherence to free cyclosporine and free tacrolimus immunosuppressant therapy. Clin Transplant 2005; 19: 7782.
  • 7
    Butler JA, Roderick P, Mullee M, Mason JC, Peveler RC. Frequency and impact of non-adherence to immunosuppressants after renal transplantation: A systematic review. Transplantation 2004; 77: 769789.
  • 8
    Takemoto SK, Pinsky BW, Schnitzler MA et al. A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients. Am J Transplant 2007; 7: 27042711.
  • 9
    Cross SA, Perry CM. Tacrolimus once-daily formulation: In the prophylaxis of transplant rejection in renal or liver allograft recipients. Drugs 2007; 67: 19311943.
  • 10
    Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713723.
  • 11
    Squifflet J, Backman L, Claesson K et al. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation 2001; 72: 6369.
  • 12
    Rostaing L, Cantarovich D, Mourad G et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005; 79: 807814.
  • 13
    Vanrenterghem Y, Van Hooff J, Squifflet J et al. Minimization of immunosuppressive therapy after renal transplantation: Results of a randomized controlled trial. Am J Transplant 2005; 5: 8795.
  • 14
    Vitko S, Wlodarczyk Z, Kyllonen L et al. Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: Results of a multicenter study. Am J Transplant 2006; 6: 531538.
  • 15
    Undre N, Wlodarczyk Z, Ostrowski M et al. Pharmacokinetics (PK) of tacrolimus for a once-daily prolonged release formulation (Advagraf®) versus twice-daily (PROGRAF®) in de novo kidney transplant recipients in a phase III multicentre study [abstract 527]. Transplantation 2008; 86: 184185.
  • 16
    Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; for the Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate for serum creatinine: A new prediction equation. Ann Intern Med 1999; 130: 461470.
  • 17
    Quiroga I, McShane P, Koo D et al. Major effects of delayed graft function and cold ischaemia time on renal allograft survival. Nephrol Dial Transplant 2006; 21: 16891696.
  • 18
    Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus: A further update of its use in the management of organ transplantation. Drugs 2003; 63: 12471297.
  • 19
    Van Hooff JP, Alloway R, Trunečka P. Four-year experience with tacrolimus once-daily prolonged release (TAC QD) in kidney, liver and heart recipients [abstract 463]. Am J Transplant 2009; 9(Suppl 2): 325.
  • 20
    Silva Jr HT, Yang HC, Abouljoud M et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients [published erratum appears in Am J Transplant 2007; 7: 1682]. Am J Transplant 2007; 7: 595608.
  • 21
    Yang H; for the Tacrolimus Extended Release De Novo Kidney Study Group. A phase III, randomized, open-label, comparative, multi-center study to assess the safety and efficacy of Prograf® (cyclosporine)/MMF in de novo kidney transplant recipients: 2 year results [abstract 144]. Am J Transplant 2007; 7(Suppl 2): 183.
  • 22
    Van Hooff JP, Alloway R, Trunečka P, Squifflet J-P. Three-year experience with tacrolimus once-daily prolonged release in kidney, liver and heart recipients. Transplantation 2008; 86(Suppl 2S): 185186.
  • 23
    Alloway R, Steinberg S, Khalil K et al. Two years postconversion from a Prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation 2007; 83: 16481651.
  • 24
    Muñoz P, Fogeda M, Bouza E, Verde E, Palomo J, Bañares R; BKV Study Group. Prevalence of BK virus replication among recipients of solid organ transplants. Clin Infect Dis 2005; 41: 17201725.
  • 25
    Wlodarczyk Z, Squifflet J-P, Ostrowski M et al. Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: A randomized, open-label trial. Am J Transplant 2009; 9: 25052513.
  • 26
    Squifflet J-P, Backman L, Claesson K et al. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation 2001; 72: 6369.
  • 27
    Poggio E, Wang X, Weinstein D et al. Assessing glomerular filtarion rate by estimation equations in kidney transplant recipients. Am J Transplant 2006; 6: 100108.
  • 28
    Banas B, Krämer B, Charpentier B et al.; for the Tacrolimus Prolonged Release Renal Study Group. Tacrolimus once-daily prolonged release versus tacrolimus twice daily in combination with MMF and steroids – a phase III multicentre renal study [abstract 1628]. Transplantation 2008; 86: 184185.